One important metric to look for in a stock is an 80 or higher Relative Strength Rating. Metsera cleared that benchmark Monday, with a jump from 78 to 82 Monday.
IBD's unique rating identifies market leadership with a 1 (worst) to 99 (best) score. The rating shows how a stock's price movement over the last 52 weeks compares to all the other stocks in our database.
Decades of market research shows that the best-performing stocks often have an RS Rating of over 80 as they launch their biggest runs.
Looking For The Best Stocks To Buy And Watch? Start Here
Metsera is trying to complete an ipo base with a 32.81 buy point. See if the stock can clear the breakout price in volume at least 40% higher than normal.
The company posted 0% EPS growth last quarter. Revenue rose 0%.
The company holds the No. 158 rank among its peers in the Medical-Biomed/Biotech industry group. ADMA Biologics, Krystal Biotech and Catalyst Pharmaceuticals are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Which Stocks Are Showing Improved Technical Action?
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
